The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

BMO Capital Markets downgraded shares of Fluence Energy (NASDAQ:FLNC – Free Report) from an outperform rating to a market perform rating in a research note released on Tuesday morning, MarketBeat.com ...

D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price target decreased by Chardan Capital from $39.00 to $30.00 in a report released on Tuesday,Benzinga reports. Chardan Capital currently ...

BMO Capital Markets maintained its Market Perform rating on Keyera Corp . (TSX:KEY:CN) (OTC: KEYUF), with a steady price target of Cdn$45.50. The stock experienced a notable increase at the opening of ...

Thursday afternoon's $25 billion sale of 30-year Treasury bonds tailed by 1.1 basis points and was met with slightly below-average bidding by nondealers, according to BMO Capital Markets strategist ...

Data released on Thursday showed that wholesale prices rose sharply in January amid persistent inflation pressures. The producer-price index increased 0.4% last month versus the 0.3% median estimate ...

SailPoint's IPO aims to raise funds for debt repayment, equity settlements, advisory fees and general corporate purposes, ...

BMO Capital Markets adjusted their outlook on DuPont (NYSE:DD), increasing the price target from the previous $105.00 to a ...

We recently published a list of the 12 Cheap Retail Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Signs of resurgent inflation shown in January's consumer-price index can't be "easily explained away" by seasonal factors, and pressure will build on the Federal Reserve to stay on hold for a ...